SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of iTeos Therapeutics, Inc. (Nasdaq – ITOS)
BALA CYNWYD – July 21, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of iTeos Therapeutics, Inc. (“iTeos Therapeutics” or the “Company”) (Nasdaq – ITOS) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Concentra Biosciences, LLC (“Concentra”). Under the terms of the transaction, iTeos Therapeutics stockholders will receive $10.047 in cash for each share of iTeos Therapeutics plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos’ product candidates that occurs within six months following the closing.
The investigation concerns whether the iTeos Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.
If you own shares of iTeos Therapeutics stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.